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tional threshold of $50,000 per QALY,manipulationwas cost-effective compared to
NSAIDs (the least costly alternative) (ICER$25,123 per QALY). NSAIDs were most
likely cost-effective at a WTP of $24,000 per QALY whereas manipulation was
most likely cost-effective between $24,000 and $50,000 per QALY. Cyclooxege-
nase-2 selective inhibitors and exercise were subject to simple dominance. The
ICER for mobilization was $381,926 per QALY. Probabilistic sensitivity analyses
suggested a high level of decision uncertainty. CONCLUSIONS: Manipulation is
cost-effective compared to NSAIDs at a conventional threshold of $50,000 per
QALY. Under varying thresholds, NSAIDs are cost effective at $24,000 per QALY.
Wewill identify themain drivers of the uncertainty surrounding the decision about
which treatment to adopt in forthcoming analyses.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic illness that implies high direct
and indirect costs for the health system, particularly when biological therapy is pre-
scribed. The aim of this study was to evaluate the cost-utility of etanercept, adali-
mumab and infliximab for the treatment of rheumatoid arthritis (RA) in Colombian
adult population. METHODS: A cost-utility analysis was performed from a Markov
modelusing3-monthcycles, assumingadult patientswithRA treated for thefirst time
with anti-TNF drugs, in combinationwithmethotrexate (MTX). The time horizonwas
2 years and we used the third party payer perspective. The model was built using
effectiveness, safety and utilitymeasures taken from international registers and clin-
ical trials. Costs were gathered locally and results are expressed in 2010 Colombian
pesos; utility wasmeasured in quality-adjusted life-years (QALY) derived fromACR50
response, compliances rates and adverse events incidence. Drug costs (fixed by regu-
lations fromMinistry of Social Protection) as well as treatment costs of moderate and
serious adverse eventsmainly tuberculosis, pneumonia and cancer included; finally a
univariate sensitivity analysis was carried out. RESULTS: QALY’s gainedwith etaner-
cept, adalimumab and infliximab were 1.4689, 1.4627 and 1.4340, respectively; and
mean estimated costs resulted in US$41, 050, US$43,175 and US$47,190, respectively.
Etanercept was the cost-saving strategy, with a cost-effectiveness ratio of US$27,945/
QALY vs. US$29,520/QALY and US$32,910/QALY in comparison to adalimumab and
infliximab, explained by providing a better safety profile, better adherence to treat-
ment and lower drug costs. The key variables in sensitivity analysis were: drug costs,
frequency of adverse events and compliance rates, and conclusions were unaffected,
even when using extreme values, supporting the robustness of the model.
CONCLUSIONS:TreatmentofRAwithetanerceptMTX is thedominant combination
in Colombia, against adalimumabMTX or infliximabMTX, by providing more
QALYs gained at lower cost.
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OBJECTIVES: To estimate the cost-effectiveness of Abatacept in combination with
Methotrexate (MTX) versus other biologic DMARDs in combination with MTX in
patients with moderate to severe active Rheumatoid Arthritis. METHODS: A se-
quences treatmentmodel was adapted for the representation of disability in terms
of HAQ Index on a 5 year horizon for a cohort of 1000 patients. Abatacept in com-
bination with MTX was compared with etanercept, rituximab, infliximab, adali-
mumab and tocilizumab, all of themassociatedwithMTX. Currency is expressed in
Peruvian soles (S/.) of 2010. RESULTS: The cost of treatment with Abatacept re-
sulted in S/. 169 263 and its effectiveness was found to be 1.96 QALY. Regarding
Etanercept, Adalimumab, Infliximab and Tocilizumab, Abatacept has shown to be
themost effective in terms of QALYs and the least expensive. Regarding Rituximab,
Abatacept has an incremental cost effectiveness ratio of S/. 75 493 perQALY gained.
CONCLUSIONS:According to thismodel and inputs, Abataceptwas found to be dom-
inant against Etanercept, Adalimumab, Infliximab y Tocilizumab, from the Health
Social Security (EsSalud) perspective for the treatment of moderate to severe active
Rheumatoid Arthritis in patients who have failed to MTX based treatment.
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OBJECTIVES: Denosumab has recently been approved in the United States for the
treatment of postmenopausal women with ostepoporosis. Denosumab, a twice
yearly 60mg injection, provides an opportunity to model the effect of improved
treatment persistence on outcomeswhen compared to the daily dosing required of
patients on 60mg raloxifene, also a second line osteoporotic therapy.METHODS: A
previously developed Markov model was used to simulate outcomes for post-
menopausal women aged 65 with a bone mineral density (BMD) of less than 2.5.
We assumed a 20-year time horizon and a managed care perspective. Modeled
health states included vertebral, hip, and wrist fractures. Disease progression pa-
rameterswere derived fromphase III clinical trials. Costswere obtained using large
epidemiologic studies. Quality-adjusted life-years (QALYS) were used to assess
outcomes, and utility weights were derived from recent systematic reviews detail-
ing utility values associated with various osteoporotic fracture states. RESULTS:
Denosumab is dominated by raloxifene, as indicated by higher costs and poorer
outcomes. Persistence rates associated with both treatments had the greatest im-
pact on resulting incremental cost-effectiveness ratios. Estimated 20-year aggre-
gated costs and QALYs per person using denosumab are $26,123 and 12.63, respec-
tively compared to $23,670 per person and 13.05 per person for raloxifene. The ICER
was most sensitive to changes in persistence rates. Raloxifene was universally
dominant under all one-way sensitivity analysis scenarios. CONCLUSIONS: Deno-
sumab is not cost-effective compared to raloxifene. Further research should assess
whether the costs associated with improved denosumab persistence are offset by
reduced fracture rates and costs of fracture treatment.
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OBJECTIVES: The objective of this research was to assess the cost-effectiveness of
Chondroitin Sulphate (CS) used as treatment of Osteoarthritis (OA) of the knee in
mexican patients from the Mexican Public Health Institution perspective.
METHODS:We developed a Markov analytical model for a cohort with 10 years to
assess costs and benefits associated with the use of CS in the treatment of OA in
Mexicans patients. Comparator for CS was normal care (gold standard treatment).
Effectiveness measure was QALYs. These values were estimated by literature re-
view validated by expert panel consensus. The direct costs, treatment of adverse
events and knee surgery in the treatment of OA were estimated. The unitary costs
were obtained from the Mexican public health institutions. All costs were calcu-
lated in 2010 Mexican Pesos (MXP). Incremental-cost-effectiveness-ratios were ex-
pressed as cost per quality-adjusted-life-year (QALY). Costs and QALYs were dis-
counted at 5%. Probabilistic sensitivity analyses via Monte Carlo simulations were
undertaken to incorporate likely distributional properties of key model
parameters. RESULTS: The QALYS increased with CS on 4.89 and with standard
treatment on 4.73. Total treatment to include CS costs increased $25,470.13 MXP,
resulting in an incremental cost per QALY in $158,587.77 MXP. This incremental
cost utility is less than 1 Mexican PIB per capita. Deterministic and probabilistic
sensitivity analyses showed the robustness of the results. CONCLUSIONS: CS is a
cost efficient and useful for the treatment of OA in public health systems
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OBJECTIVES: The relationship between out-of-pocket (OOP) healthcare costs with
productivity is not well known. This study explores the relationship of OOP health-
care costs on productivity.METHODS: Participants self-identifiedwith RA and aged
18 completed an internet-based cross-sectional survey in 1Q2009. Self-reported
productivity loss including absenteeism, presenteeism, overall work impairment
and activity impairment expressed as impairment percentages, weremeasured by
the Work Productivity and Activity Impairment questionnaire. Participants were
asked about RA-related and overall monthly OOP healthcare costs. Negative bino-
mial regressionmodelswere developed to adjust for age, gender, ethnicity, income,
education, andmarital status.RESULTS: 455 RApatients participated in the survey.
Average age was 52 years, 67% were female, 36% were employed, and 23% were on
short- or long-term disability. More than half (53%) reported annual household
incomes between $50-100K, and 30% were college educated. Overall monthly OOP
costs were: $0-$50 for 54.1%, $51-$100 for 19.3%, $101-$200 for 15.8%, and$200 for
10.8%. Among employed patients, the rates of absenteeism, presenteeism, and
overall work impairment were 13.7%, 23.7% and 28.9%, respectively. Both em-
ployed and unemployed patients reported 58.4% impairment in daily activities.
Significantly greater productivity loss (presenteeism, b  1.01, p  0.038) and ac-
tivity impairment (b  0.21, p  0.006) were observed among patients with overall
OOP costs $200, and significantly greater activity impairment was observed
among theOOP costs category of $101-200 (b 0.15, p 0.026) as compared to those
with OOP costs between $0-50 after adjusting for patient demographics.
CONCLUSIONS: Higher monthly OOP costs were associated with higher activity
impairment and lower productivity; however, due to cross-sectional study design,
direction of associations cannot be determined. Shifting healthcare costs to em-
ployees may be associated with productivity loss. Further research is needed to
determine long-term impact of OOP healthcare costs on work productivity.
Muscular-Skeletal Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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